blu

Onyx Pharmaceuticals: Is Nexavar the Next Avastin?

In my case, the side effects are manageable. I will be half way through the trial in another week. (The trial duration is 54 weeks).
Side effects have improved in the last 12 weeks, and I am very optimistic about the future.
Sorafenib has been receiving good reviews in Europe and around the world. I have a google search running constantly for news on kidney cancer and almost every day there is news about this drug.
I believe you are quite correct in your outlook.
Thanks for the well wishes.

Onyx Pharmaceuticals: Is Nexavar the Next Avastin?

I am participating in a nationwide clinical trial through M.D. Anderson Cancer Center in Houston. The trial is a double blind study to ascertain the effectiveness of Sorafenib, Sutent, and a placebo in an adjuvant setting for kidney cancer.

This trial has grown considerably since I began participation as they continue to add participants. This is partially due to a high drop out rate due to significant side effects from the drugs.

I am certain that I am taking Sorafenib as my side effects do not subside during the rest period from Sutent.

I am hopeful this adjuvant application is successful as kidney cancer is notorious for returning after surgery in other parts of the body. As the trial size expands, the date of final analysis is pushed farther out in the future. No chemo treatment has been found to be effective in staving off the return of the disease as yet. If Sorafenib proves to be beneficial in this application, then sales will certainly be bolstered significantly.